Sound fa­mil­iar? Chi­na/US biotech hy­brid lands rights to can­cer drugs, cash and a team of de­vel­op­ment vets to launch On­colo­gie

Look­ing for a new and sud­den­ly pop­u­lar busi­ness mod­el?

An­oth­er transpa­cif­ic biotech has launched with the back­ing of an emerg­ing group of ven­ture in­vestors in Chi­na as well as a plan to build a pipeline of can­cer drugs that can be swift­ly de­vel­oped for the boom­ing Asian mar­ket. Not sur­pris­ing­ly, they’re get­ting start­ed by fo­cus­ing on drug com­bi­na­tions us­ing red-hot check­point ther­a­pies to amp up re­spons­es for tar­get­ed ther­a­pies.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN